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Novel influenza A (H1N1) 2009 infection in the 
pediatric patients with hematologic and oncologic 
diseases in the Yeungnam region in Korea
Purpose: Natural history and consequences of the novel 2009 
influenza A H1N1 (2009 H1N1) infection in immunocompromised 
pediatric patients are not yet fully understood. In this study, we 
investigated the clinical features and outcomes of the 2009 H1N1 
infection in pediatric patients with hematological and oncological 
diseases.
Methods: We retrospectively reviewed the medical records of 528 
patients who had hematological and oncological diseases and who 
were treated at 7 referral centers located in the Yeungnam region. 
Among the 528 patients, 27 with definite diagnosis of 2009 H1N1 in-
fection were the subjects of this study. All patients were divided into 
the following 3 groups: patients who were receiving chemotherapy 
(group 1), patients who were immunosuppressed due to a non-
malignant hematological disease (group 2), and patients who were off 
chemotherapy and had undergone their last chemotherapy course 
within 2 years from the influenza A pandemic (group 3).
Results: All 28 episodes of 2009 H1N1 infection were treated with 
the antiviral agent oseltamivir (Tamiflu
®), and 20 episodes were 
treated after hospitalization. Group 1 patients had higher frequencies 
of lower respiratory tract infection and longer durations of fever 
and hospitalization as compared to those in group 2. Ultimately, all 
episodes resolved completely with no complications.
Conclusion: These results suggest that early antiviral therapy did 
not influence the morbidity or mortality of pediatric patients with 
hematological and oncological diseases in the Yeungnam region of 
Korea after the 2009 H1N1 infection. However, no definite conclusions 
can be drawn because of the small sample size.
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Introduction
A novel swine-originating influenza A H1N1 virus spread rapidly 
around the world in 2009, and on June 11, 2009, the World Health 
Organization raised the pandemic alert level to phase 6, indicating 
that a global pandemic had begun
1).
Initial reports suggested that illness associated with the pandemic 
2009 influenza H1N1 (2009 H1N1) infection might be mild 
compared with the 1918 influenza pandemic
2, 3). However, recently 
published series that included 122 children with confirmed 2009 
H1N1 infection, reported a high prevalence of underlying medical 
conditions and described the need for intensive care and mechanical 
ventilation in 20% and 10% of patients, respectively
4). In Korea, 
Shin et al.
5) reported that high-risk pediatric patients had an elevated 
mortality rate following infection with novel influenza A (H1N1) 
virus.
In May, 2009, the first case of the 2009 H1N1 infection was 
identified in Korea. By February, 2010, 243 deaths had been re-
ported
6). Risk factors for severe complications of the 2009 H1N1 
infection include chronic lung disease, heart disease, pregnancy, 
immunosuppression, and neurodevelopmental disorders
3, 5, 7). Patients 
with hematological and oncological diseases are more susceptible 
to acquiring infections than the general population and potentially 
develop more complications. Because of disruptions in both innate 
and acquired immunity, even organisms with low virulence are 
able to cause significant morbidity and mortality
8). There are several 
reports that the 2009 H1N1 infection in adults with hematological 
malignancies may have lead to severe complications
9-11), although 49 
adult patients with cancer and/or hematopoietic stem cell transplant 
(HSCT) who were diagnosed with the 2009 H1N1 infection had 
mild symptoms
12). However, the reports on the natural history and 
the consequences of the 2009 H1N1 infection among the pediatric 
immunocompromised patients are very rare. Launes
13)  reported 
that the 2009 H1N1 infection in pediatric patients with acute 
lymphoblastic leukemia under maintenance treatment had a mild 
disease while children receiving intensive treatment had more severe 
diseases. Caselli et al.
14) reported that the 2009 H1N1 infection in 
children with cancer was not the cause of death in any case. 
This study was conducted to investigate the clinical features and 
the outcomes of the 2009 H1N1 infection in pediatric patients with 
the hematologic and oncologic diseases in the Yeungnam region of 
Korea.
Materials and methods
1. Patients
We retrospectively reviewed the medical records of the 528 
patients under the age of 20 years who had hematological and on-
cological diseases and were treated at seven referral centers located 
in the Yeungnam region, between September, 2009 and February, 
2010 (pandemic influenza A 2009). All patients were divided into 
three groups. Group 1 consisted of the patients who were receiving 
chemotherapy for malignancy during the study period (n=245). 
Group 2 consisted of patients who were immunosuppressed due 
to a non-malignant hematological disease, such as aplastic anemia, 
and those who had undergone a splenectomy for the treatment of 
hemolytic anemia (n=90). Group 3 consisted of patients who were 
off chemotherapy and had received their last chemotherapy within 2 
years from the influenza A pandemic (n=193).
Of these 528 patients, 27 patients identified as having the 2009 
H1N1 infections were the subjects of this study. None of them except 
one were vaccinated prior to 2009 H1N1 outbreak. 
2. Methods
Laboratory diagnosis of the 2009 H1N1 infection was confirmed 
by the real-time reverse transcriptase-polymerase-chain-reaction 
assays (Exicyclor
Ⓡ96, Bioneer Inc, Alameda, CA, USA; Applied 
Biosystems 7500 Real-Time PCR System, Applied Biosystem, Foster 
City, CA, USA) of a nasopharyngeal swab. Upper respiratory tract 
infection was defined as the presence of pharyngeal congestion and/
or rhinorrhea in the absence of lower respiratory tract symptoms, 
with normal chest X-ray findings. Lower respiratory tract infection 
was defined as the presence of the clinical findings such as coughing, 
hypoxia, dyspnea, wheezing, and rales with new pulmonary 
infiltrations on chest X-ray.
Laboratory data were collected and analyzed. Neutropenia was 
defined as an absolute neutrophil count (ANC) of less than 1,000/
µL in infants between 2 weeks and 1 year of age and less than 1,500/
µL beyond 1 year of age. Severe neutropenia was defined as an 
ANC of less than 500/µL. Lymphopenia was defined as an absolute 
lymphocyte count (ALC) of less than 1,800/µL in children under 2 
years of age and less than 1,000/µL in children beyond 2 years of age.
3. Statistical analyses
Results are expressed as mean values, median values, and ranges. 
Statistical analyses were performed using Fisher’s exact test, Kruskall-
Wallis test, and the Mann-Whitney test. Significance was set at P< 
0.05. The SPSS (version 18.0, SPSS Inc, Chicago, IL, USA) was used 
for statistical analyses.Korean J Pediatr 2011;54(3):117-122 • DOI: 10.3345/kjp.2011.54.3.117    119
Results
1. Patients
Twenty-seven patients were diagnosed with the 2009 H1N1 
infection and one patient had two separate episodes.
The median age of the 27 patients was 8±4.6 years and 15 (55%) 
were males. Ten patients (37%) were aged between 5 and 10 years 
old. Of the 28 episodes, 17 (60%) belonged to group 1, three (11%) 
belonged to group 2, and eight (29%) belonged to group 3. 
Of the group 1 patients, 11 (41%) had leukemia, four (15%) had 
lymphoma, and one had Ewing sarcoma. A 6-month-old male infant 
was diagnosed with acute myeloblastic leukemia in November, 2009 
and at the same time he was found to have the 2009 H1N1 infection. 
He received induction chemotherapy with the antiviral agent 
Tamiflu. Three patients in group 2 had non-malignant hematological 
diseases. Of the group 3 patients, six had leukemia and one patient 
each had lymphoma and neuroblastoma (Table 1).
No patient had a preexisting chronic lung disease, congenital heart 
disease, or neurodevelopmental disorder.
Ten episodes (35.7%) were confirmed in October, 2009 and nine 
(32.2%) in November, 2009. Similar distributions in the number of 
confirmed patients and in the number of patients with influenza-like 
illness of the Korean population reported by committees of the Korea 
Centers for Disease Control and Prevention were observed during the 
study period (Fig. 1).
2. Clinical presentations
The common symptoms presented at the time of diagnosis 
of the 2009 H1N1 were coughing and fever among all groups. 
Rhinorrhea/nasal stuffiness and sputum are the next common. The 
gastrointestinal symptoms were not seen other than vomiting (n=3, 
11%). Neurological symptoms of headache were noted in 8 patients 
(28%) totally, and 4 cases in group 1. No statistical significant 
differences between groups were detected in the clinical features 
except duration of fever (Table 2). The mean duration of fever was 
3.7±3.1 days in group 1, 2.7±0.6 days in group 2, 1.1±1.1 days in 
group 3, and totally 2.8±2.7 days. The mean duration of fever was 
Table 1. Baseline Characteristics of Patients with Hematologic and 
Oncologic Diseases in the Yeungnam Region with Definite Diagnosis of 
2009 H1N1 Infection
Characteristics Data
Demographic factor
Age, year (range) 10.4±4.6 (0.6-17.8)
Male/Female (%) 15 (55)/12 (45)
Diagnosis
  Group 1 (n=16)
    Leukemia 11 (41)
    Lymphoma 4 (15)
  Ewing sarcoma 1 (3.7)
  Group 2 (n=3)
    Aplastic anemia 1 (3.7)
    MDS* 1 (3.7)
    Hereditary spherocytosis (p splenectomy) 1 (3.7)
  Group 3 (n=8)
    Leukemia 6 (22)
    Lymphoma 1 (3.7)
    Neuroblastoma 1 (3.7)
Abbreviation: MDS, myelodysplastic syndrome
*Refractory anemia dependent on transfusion
Fig. 1. Number of 2009 H1N1 infections with hematologic and oncologic 
disease by month, i.e., between September 2009 and February 2010, 
in the region of Yeungnam (n=28). Note: Twenty-eight episodes of 2009 
H1N1 infection were observed in 27 patients; hence, 1 patient was 
infected twice.
Table 2. Clinical Features of Patients with Hematologic and Oncologic 
Diseases in the Yeungnam Region with Definite Diagnosis of 2009 
H1N1 Infection
Clinical features
Number*
Total 
(%)
P 
value Group 1 
(n=17)
Group 2 
(n=3)
Group 3
 (n=8)
Contact history with H1N1 pt 2 1 2 5 (18) 0.55
Coughing 16 3 7 26 (93) 0.73
Fever 16 3 5 24 (86) 0.08
Rhinorrhea/Nasal stuffiness 9 2 5 16 (57) 0.85
Sputum 10 3 2 15 (53) 0.07
Myalgia 6 1 1 8 (28) 0.49
Headache 4 1 3 8 (28) 0.78
Vomiting 1 1 1 3 (11) 0.36
Dyspnea 2 0 0 2 (7) 0.50
Tachypnea 2 0 0 2 (7) 0.50
Drowsiness 0 0 0 0
Diarrhea 0 0 0 0
Abdominal pain 0 0 0 0
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significantly longer in group 1 (P=0.022).
3. Laboratory findings
Of the 28 episodes, complete blood cell counts were performed in 
21 episodes. Laboratory studies were performed in all cases in group 1 
and 2 (17 and 3 patients each), but only in one of the eight patients in 
group 3. Therefore, statistical comparison was not made. The median 
white blood cell count was 2.82×10
3/µL (range, 0.1‒11.2×10
3/µL). Of 
the 21 episodes, leucopenia was revealed in 15 (71%), neutropenia in 
11 (52%), severe neutropenia in 6 (28.5%). Lymphopenia was seen 
in 18 (85%) and the median ALC was 328/µL (range, 19‒3,254/
µL). Thrombocytopenia was noted in 12 (57%). Twelve (57%) had 
an elevated alanine aminotransferase (ALT) level (>45 IU/L) and 
aspartate aminotransferase (AST) level (>55 IU/L for children <10 
years of age and >45 IU/L for children ≥10 years of age). C-reactive 
protein (CRP) was measured in 20 episodes, and the mean CRP level 
was 3.29±3.71 mg/dL and 19 (67.8%) had elevated levels (Table 3).
Chest X-rays were taken in 25 episodes; 11 (44%) had radiographic 
abnormalities with evidence of lower respiratory tract disease.
4. Outcomes
For 20 (71%) patients of total 28 episodes were treated after 
hospitalization. The median duration of the hospitalization was 8 
(range, 3‒87) days. In three cases, the durations of hospitalization 
were longer than 15 days. They had been newly diagnosed as Ewing 
sarcoma, lymphoma, and acute myeloblastic leukemia, and their 
duration of admission was prolonged for chemotherapy.
Significant differences between groups were detected in the 
frequencies of lower respiratory tract infection (P=0.03), admission 
(P<0.001), and durations of fever (P=0.022) and hospitalization 
(P=0.001). Group 1 had higher frequencies of lower respiratory tract 
infection and longer durations of fever and hospitalization (Table 
4). Between the patients with lymphopenia and neutropenia, no 
difference was detected in the frequency of lower respiratory tract 
infection or duration of fever or hospitalization (Table 5).
All episodes were treated with oseltamivir (Tamiflu
Ⓡ, Roche, Basel, 
Switzerland) at a dose calculated based on patient body weight
12). All 
treated patients tolerated Tamiflu well. Tamiflu was administered for 
a median of 1 day (range, 1‒9 days) after onset of initial symptoms. 
Within a median of 1 day initial symptoms had subsided. As si-
multaneous bacterial infection could not be ruled out, 20 cases of 
hospitalized patients received systemic antibiotics in addition to 
Table 3. Initial Laboratory Findings of the Patients with Hematologic and Oncologic Diseases in the Yeungnam Region Confirmed with the 2009 H1N1 
Infection
Laboratory findings on admission Group 1 (n=17) Group 2 (n=3) 3 (n=1) Mean
WBC, median(range), 10
3/μL 2.81 (0.1-8.30) 1.88 (0.48-11.22) 13.4 2.82 (0.1-11.22)
Hemoglobin (SD), g/dl 10.5 (±1.7) 6.2 (±1.4) 12.7 10.0 (±2.4)
Platelet (SD), 10
3/μL 152.6 (±88.1) 288 (±486) 203 188.8 (±182.3)
ANC, median (range), cell/μL 835 (0-4067) 750 (221-5947) 8,549 993 (0-5947)
ALC, median (range), cell/μL 318 (19-1610) 964 (206-3254) 3,430 328 (19-3254)
ESR (SD), mmH 18.4 (±18.5) 27.3 (±30.3) 17.2 (±20.8)
CRP(SD), mg/dL 3.53 (±3.87) 3.28 (±2.23) 0.31 3.29 (±3.71)
Na (SD), mg/dL 138.6 (±2.68) 136.6 (±3.29) 139.5 138.2 (±2.86)
K (SD), mEq/L 3.98 (±0.58) 4.00 (±0.45) 4.32 4.00 (±0.56)
BUN (SD), mg/dL 6.42 (±3.28) 8.68 (±1.33) 12 7.0 (±3.36)
Creatinine (SD), mg/dL 0.44 (±0.19) 0.72 (±0.09) 0.51 0.48 (±0.20)
AST (SD), u/L 50.8 (±27.7) 36.6 (±13.8) 18 47.2 (±27.3)
ALT (SD), u/L 93.1 (±85.6) 45.0 (±21.6) 8 82.1 (±78.8)
LDH  (SD), u/L 921.3 (±834.0) 423 (±121) 324 761.9 (±756.3)
Total protein (SD), g/dL 6.19 (±1.04) 6.83 (±0.35) 7 6.34 (±1.00)
Albumin (SD), g/dL 4.02 (±0.75) 4.4 (±0.2) 4.3 4.09 (±0.70)
Abbreviations: WBC, white blood cell count; SD, standard deviation; ANC, absolute neutrophil count; ESR, erythrocyte sedimentation rate; CRP, c-reactive 
protein; BUN, blood urea nitrogen; AST, aspartate aminotransferase; ALT, alanine aminotransferase.
Table 4. Outcomes of the 2009 H1N1 Infection according to Groups
Group 1
(n=17)
Group 2
(n=3)
Group 3
(n= 8)
P 
value
LRTI (No.) 9 2 0 0.03
Hospitalization (No.) 16 3 1 <0.001
Mean duration of fever (days) 3.7±3.1 2.7±0.6 1.1±1.1 0.02
Median days of hospitalization 9±19.4 5±2.00 0±2.47 0.001
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Tamiflu treatment. Six cases received systemic antifungal agents, too. 
Of the six patients with severe neutropenia, one patient who received 
maintenance chemotherapy for acute lymphoblastic leukemia was 
treated with granulocyte colony-stimulating factor.
After recovery from 2009 H1N1 infection, one patient died of 
disseminated intravascular coagulation and septic shock 2 weeks later. 
Influenza infection was not directly responsible for any death.
Discussion
Seasonal influenza A infection has been associated with high 
mor  bidity and mortality in immunocompromised patients. In 
pre  vious retrospective reports, seasonal influenza among patients 
with impaired immunity was associated with higher incidences of 
pneumonia and fatality. Chemaly et al.
15) reported the overall mor-
tality rate for community acquired respiratory viral pneumonia 
was 15% among HSCT recipients and patients with hematological 
malignancies.  Mendoza Sanchez et al. noted that common respi-
ratory virus infections in children with cancer or HIV infection have 
significant morbidity
16). Pediatric oncology patients experienced 
significant influenza-associated morbidities
17).
The clinical outcomes of the 2009 H1N1 infection in the pediatric 
patients with hematological and oncological diseases are not fully 
understood and are still being defined. Several studies have reported 
fatal cases in adults with cancers and in HSCT recipients
9‒11). 
Recently, Caselli et al.
14) reported that the 2009 H1N1 infection in 
children with cancer was not the cause of death in any case; however, 
it resulted in reduced intensity of anti-cancer therapy.
In this retrospective study, we sought to investigate the clinical 
fea  tures and the outcomes of the 2009 H1N1 infection in the pedi-
atric patients with hematological and oncological diseases who 
were potentially vulnerable to infections because of underlying 
immunosuppression. No patient required mechanical ventilation 
and no deaths were observed to be directly related to the 2009 H1N1 
infections in this study. Most patients had mild disease and they 
recovered completely without complications related to the 2009 
H1N1 infection.
When all episodes were grouped by disease status, statistically 
significant differences were observed between the groups in duration 
of fever and the hospitalization and development of lower respiratory 
tract infection. Most group 1 patients, who were on chemotherapy 
for their malignancy, had low lymphocyte and neutrophil counts 
at diagnosis of the 2009 H1N1 infection. Indeed, 10 patients 
had lymphopenia and nine had neutropenia. Previous studies in 
immunocompromised hosts with seasonal influenza found that 
lym  phopenia was associated with prolonged shedding, a higher 
chance of the virus developing drug resistance during treatment, 
and pneumonia
2, 11, 15, 18). We did not obtain information on viral 
shedding; however, our study shows that all patients with the 2009 
H1N1 infections recovered clinically, regardless of lymphopenia or 
neutropenia.
These patients have been closely monitored and carefully treated. 
Because of the nature of the patients with hematologic and oncologic 
diseases, they were not readily vaccinated but tend to visit hospital 
earlier. Therefore, active treatment was possible at early stage of the 
disease.
This study had some limitations. The small sample size of this 
study does not allow for definite conclusions about the 2009 
H1N1 infections in hematologic and oncologic pediatric patients. 
It is unclear whether patients treated in the Yeungnam region 
were representative of the greater population of hematological and 
oncological pediatric patients.
In summary, most pediatric patients with hematological and 
oncological diseases in the Yeungnam region, Korea, had favorable, 
and not fatal, courses from the 2009 H1N1 infection. As with the 
general population, coughing and fever were the most common 
symptoms. We conclude that pediatric patients with hematological 
and oncological diseases did not have increased morbidity or 
mortality following infection with H1N1 infection if they were 
treated with the antiviral agent Tamiflu during the early stages.
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